{ "version": "2.2", "instance": { "ea0281765-20f_purple.htm": { "nsprefix": "ppbt", "nsuri": "http://Purplebiotech.com/20251231", "dts": { "inline": { "local": [ "ea0281765-20f_purple.htm" ] }, "schema": { "local": [ "ppbt-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd", "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "ppbt-20251231_cal.xml" ] }, "definitionLink": { "local": [ "ppbt-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "ppbt-20251231_lab.xml" ] }, "presentationLink": { "local": [ "ppbt-20251231_pre.xml" ] } }, "keyStandard": 247, "keyCustom": 101, "axisStandard": 22, "axisCustom": 2, "memberStandard": 28, "memberCustom": 48, "hidden": { "total": 186, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 165, "http://Purplebiotech.com/20251231": 15, "http://xbrl.sec.gov/dei/2025": 6 }, "contextCount": 401, "entityCount": 1, "segmentCount": 88, "elementCount": 812, "unitCount": 5, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 863, "http://xbrl.sec.gov/dei/2025": 46, "http://xbrl.sec.gov/cyd/2025": 8, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation", "longName": "995300 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c0", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R3": { "role": "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Consolidated Statements of Financial Position", "shortName": "Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "ifrs-full:CurrentInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R4": { "role": "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "longName": "995302 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Other Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R5": { "role": "http://Purplebiotech.com/role/ShareholdersEquityType2or3", "longName": "995303 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c59", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c59", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R6": { "role": "http://Purplebiotech.com/role/ConsolidatedCashFlow", "longName": "995304 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R7": { "role": "http://Purplebiotech.com/role/General", "longName": "995305 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R8": { "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements", "longName": "995306 - Disclosure - Basis of Preparation of the Consolidated Financial Statements", "shortName": "Basis of Preparation of the Consolidated Financial Statements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R9": { "role": "http://Purplebiotech.com/role/MaterialAccountingPolicies", "longName": "995307 - Disclosure - Material Accounting Policies", "shortName": "Material Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R10": { "role": "http://Purplebiotech.com/role/IntangibleAssets", "longName": "995308 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R11": { "role": "http://Purplebiotech.com/role/CashandCashEquivalents", "longName": "995309 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R12": { "role": "http://Purplebiotech.com/role/Leases", "longName": "995310 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R13": { "role": "http://Purplebiotech.com/role/OtherCurrentAssets", "longName": "995311 - Disclosure - Other Current Assets", "shortName": "Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R14": { "role": "http://Purplebiotech.com/role/OtherPayables", "longName": "995312 - Disclosure - Other Payables", "shortName": "Other Payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R15": { "role": "http://Purplebiotech.com/role/Equity", "longName": "995313 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R16": { "role": "http://Purplebiotech.com/role/ShareBasedPaymentArrangements", "longName": "995314 - Disclosure - Share-Based Payment Arrangements", "shortName": "Share-Based Payment Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R17": { "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties", "longName": "995315 - Disclosure - Transactions and Balances with Related Parties", "shortName": "Transactions and Balances with Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R18": { "role": "http://Purplebiotech.com/role/CommitmentsandContingentLiabilities", "longName": "995316 - Disclosure - Commitments and Contingent Liabilities", "shortName": "Commitments and Contingent Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R19": { "role": "http://Purplebiotech.com/role/ResearchandDevelopmentExpenses", "longName": "995317 - Disclosure - Research and Development Expenses", "shortName": "Research and Development Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R20": { "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses", "longName": "995318 - Disclosure - Sales, General and Administrative Expenses", "shortName": "Sales, General and Administrative Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R21": { "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNet", "longName": "995319 - Disclosure - Finance Expense (Income), Net", "shortName": "Finance Expense (Income), Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R22": { "role": "http://Purplebiotech.com/role/TaxesonIncome", "longName": "995320 - Disclosure - Taxes on Income", "shortName": "Taxes on Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R23": { "role": "http://Purplebiotech.com/role/EmployeeBenefits", "longName": "995321 - Disclosure - Employee Benefits", "shortName": "Employee Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R24": { "role": "http://Purplebiotech.com/role/FinancialInstruments", "longName": "995322 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R25": { "role": "http://Purplebiotech.com/role/SubsequentEvents", "longName": "995323 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R28": { "role": "http://Purplebiotech.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R29": { "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables", "longName": "996001 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Tables)", "shortName": "Basis of Preparation of the Consolidated Financial Statements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://Purplebiotech.com/role/IntangibleAssetsTables", "longName": "996002 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R31": { "role": "http://Purplebiotech.com/role/CashandCashEquivalentsTables", "longName": "996003 - Disclosure - Cash and Cash Equivalents (Tables)", "shortName": "Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R32": { "role": "http://Purplebiotech.com/role/LeasesTables", "longName": "996004 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R33": { "role": "http://Purplebiotech.com/role/OtherCurrentAssetsTables", "longName": "996005 - Disclosure - Other Current Assets (Tables)", "shortName": "Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfOtherCurrentAssettextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfOtherCurrentAssettextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R34": { "role": "http://Purplebiotech.com/role/OtherPayablesTables", "longName": "996006 - Disclosure - Other Payables (Tables)", "shortName": "Other Payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R35": { "role": "http://Purplebiotech.com/role/EquityTables", "longName": "996007 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R36": { "role": "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables", "longName": "996008 - Disclosure - Share-Based Payment Arrangements (Tables)", "shortName": "Share-Based Payment Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R37": { "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables", "longName": "996009 - Disclosure - Transactions and Balances with Related Parties (Tables)", "shortName": "Transactions and Balances with Related Parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R38": { "role": "http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables", "longName": "996010 - Disclosure - Research and Development Expenses (Tables)", "shortName": "Research and Development Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R39": { "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables", "longName": "996011 - Disclosure - Sales, General and Administrative Expenses (Tables)", "shortName": "Sales, General and Administrative Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R40": { "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables", "longName": "996012 - Disclosure - Finance Expense (Income), Net (Tables)", "shortName": "Finance Expense (Income), Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R41": { "role": "http://Purplebiotech.com/role/EmployeeBenefitsTables", "longName": "996013 - Disclosure - Employee Benefits (Tables)", "shortName": "Employee Benefits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R42": { "role": "http://Purplebiotech.com/role/FinancialInstrumentsTables", "longName": "996014 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R43": { "role": "http://Purplebiotech.com/role/GeneralDetails", "longName": "996015 - Disclosure - General (Details)", "shortName": "General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c118", "name": "ppbt:StockholdersEquityReversesStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c85", "name": "ppbt:PercentageOfContractToAcquire", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R44": { "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails", "longName": "996016 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details)", "shortName": "Basis of Preparation of the Consolidated Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c0", "name": "ppbt:FunctionalCurrency", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:FunctionalCurrency", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R45": { "role": "http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable", "longName": "996017 - Disclosure - Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)", "shortName": "Basis of Preparation of the Consolidated Financial Statements - Schedule of Data on Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R46": { "role": "http://Purplebiotech.com/role/IntangibleAssetsDetails", "longName": "996018 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c86", "name": "ppbt:EquityMethodInvestmentsOwnershipPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c86", "name": "ppbt:EquityMethodInvestmentsOwnershipPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R47": { "role": "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable", "longName": "996019 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c92", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R48": { "role": "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable", "longName": "996020 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c99", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R49": { "role": "http://Purplebiotech.com/role/LeasesDetails", "longName": "996021 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c106", "name": "ppbt:AgreementLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c106", "name": "ppbt:AgreementLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R50": { "role": "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable", "longName": "996022 - Disclosure - Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)", "shortName": "Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c107", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c110", "name": "ifrs-full:RightofuseAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R51": { "role": "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable", "longName": "996023 - Disclosure - Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)", "shortName": "Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:LeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "ifrs-full:LeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R52": { "role": "http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable", "longName": "996024 - Disclosure - Leases - Schedule of Amounts Recognized in Profit or Loss (Details)", "shortName": "Leases - Schedule of Amounts Recognized in Profit or Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R53": { "role": "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable", "longName": "996025 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)", "shortName": "Other Current Assets - Schedule of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c2", "name": "ppbt:GovernmentAuthorities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfOtherCurrentAssettextBlock", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "ppbt:GovernmentAuthorities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfOtherCurrentAssettextBlock", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R54": { "role": "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable", "longName": "996026 - Disclosure - Other Payables - Schedule of Other Payables (Details)", "shortName": "Other Payables - Schedule of Other Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R55": { "role": "http://Purplebiotech.com/role/EquityDetails", "longName": "996027 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c0", "name": "ppbt:NonVotingSeniorPreferredShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:NonVotingSeniorPreferredShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R56": { "role": "http://Purplebiotech.com/role/ScheduleofShareCapitalTable", "longName": "996028 - Disclosure - Equity - Schedule of Share Capital (Details)", "shortName": "Equity - Schedule of Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c168", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c168", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R57": { "role": "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable", "longName": "996029 - Disclosure - Equity - Schedule of Changes in Share Capital (Details)", "shortName": "Equity - Schedule of Changes in Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c3", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:NumberOfIssuanceShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R58": { "role": "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable", "longName": "996030 - Disclosure - Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)", "shortName": "Equity - Schedule of the Information Relating to Non-Controlling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:OtherNoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "ifrs-full:OtherNoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R59": { "role": "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails", "longName": "996031 - Disclosure - Share-Based Payment Arrangements (Details)", "shortName": "Share-Based Payment Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c226", "name": "ppbt:OptionExerciseOrdinaryShare", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R60": { "role": "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable", "longName": "996032 - Disclosure - Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)", "shortName": "Share-Based Payment Arrangements - Schedule of Number and Weighted Average Exercise Prices of Share Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c3", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c68", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R61": { "role": "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable", "longName": "996033 - Disclosure - Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)", "shortName": "Share-Based Payment Arrangements - Schedule of Number of RSUs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c3", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c46", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R62": { "role": "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "longName": "996034 - Disclosure - Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)", "shortName": "Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R63": { "role": "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable", "longName": "996035 - Disclosure - Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)", "shortName": "Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c238", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R64": { "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails", "longName": "996036 - Disclosure - Transactions and Balances with Related Parties (Details)", "shortName": "Transactions and Balances with Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c0", "name": "ppbt:PercentageOfCapacityOfAnAdvisor", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:PercentageOfCapacityOfAnAdvisor", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R65": { "role": "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable", "longName": "996037 - Disclosure - Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)", "shortName": "Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c244", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c244", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R66": { "role": "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "longName": "996038 - Disclosure - Commitments and Contingent Liabilities (Details)", "shortName": "Commitments and Contingent Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c257", "name": "ifrs-full:GainsOnLitigationSettlements", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c257", "name": "ifrs-full:GainsOnLitigationSettlements", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R67": { "role": "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable", "longName": "996039 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)", "shortName": "Research and Development Expenses - Schedule of Research and Development Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c258", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R68": { "role": "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable", "longName": "996040 - Disclosure - Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)", "shortName": "Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c241", "name": "ifrs-full:WagesAndSalaries", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c241", "name": "ifrs-full:WagesAndSalaries", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R69": { "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails", "longName": "996041 - Disclosure - Finance Expense (Income), Net (Details)", "shortName": "Finance Expense (Income), Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c0", "name": "ppbt:GainLossOnWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:GainLossOnWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R70": { "role": "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable", "longName": "996042 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Expenses (Details)", "shortName": "Finance Expense (Income), Net - Schedule of Finance Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:FeeAndCommissionExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:FeeAndCommissionExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R71": { "role": "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable", "longName": "996043 - Disclosure - Finance Expense (Income), Net - Schedule of Finance Income (Details)", "shortName": "Finance Expense (Income), Net - Schedule of Finance Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:InterestIncomeOnDeposits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:InterestIncomeOnDeposits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R72": { "role": "http://Purplebiotech.com/role/TaxesonIncomeDetails", "longName": "996044 - Disclosure - Taxes on Income (Details)", "shortName": "Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R73": { "role": "http://Purplebiotech.com/role/EmployeeBenefitsDetails", "longName": "996045 - Disclosure - Employee Benefits (Details)", "shortName": "Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c0", "name": "ppbt:EmployeeBenefitBonus", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ppbt:EmployeeBenefitBonus", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R74": { "role": "http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable", "longName": "996046 - Disclosure - Employee Benefits - Schedule of Post-Employee Benefits (Details)", "shortName": "Employee Benefits - Schedule of Post-Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ShorttermEmployeeBenefitsExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:ShorttermEmployeeBenefitsExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R75": { "role": "http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable", "longName": "996047 - Disclosure - Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)", "shortName": "Employee Benefits - Schedule of Defined Contribution Plan in Respect of its Employees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R76": { "role": "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "longName": "996048 - Disclosure - Financial Instruments (Details)", "shortName": "Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c273", "name": "ifrs-full:ProceedsFromExerciseOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R77": { "role": "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable", "longName": "996049 - Disclosure - Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)", "shortName": "Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c308", "name": "ppbt:IncomelossFromChangeInExchangeRateDown", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c308", "name": "ppbt:IncomelossFromChangeInExchangeRateDown", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R78": { "role": "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable", "longName": "996050 - Disclosure - Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)", "shortName": "Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c3", "name": "ifrs-full:DerivativeFinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "ifrs-full:DerivativeFinancialAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R79": { "role": "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable", "longName": "996051 - Disclosure - Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)", "shortName": "Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c385", "name": "ppbt:FairValueMeasurementBalance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c389", "name": "ppbt:FairValueMeasurementBalance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "span", "td", "tr", "table", "ppbt:ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } }, "R80": { "role": "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "longName": "996052 - Disclosure - Financial Instruments - Schedule of Fair Value Measurement (Details)", "shortName": "Financial Instruments - Schedule of Fair Value Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c398", "name": "ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "b", "span", "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c398", "name": "ppbt:ExpectedDividendAsPercentageShareOptionsdividendYield", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "b", "span", "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true, "unique": true } }, "R81": { "role": "http://Purplebiotech.com/role/SubsequentEventsDetails", "longName": "996053 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c119", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "first": true }, "uniqueAnchor": { "contextRef": "c399", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0281765-20f_purple.htm", "unique": true } } }, "tag": { "ppbt_ADSMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ADSMember", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/GeneralDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ADS \u2013 USD", "verboseLabel": "ADS [Member]", "label": "ADSMember" } } }, "auth_ref": [] }, "ppbt_ATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ATMProgramMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Program [Member]", "label": "ATMProgram Member" } } }, "auth_ref": [] }, "ppbt_AccountPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AccountPayablesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable [Member]", "label": "Account Payables Member" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other", "label": "Accruals classified as current" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r406" ] }, "ppbt_AcquisitionOfSubsidiaryNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AcquisitionOfSubsidiaryNetOfCashAcquired", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of subsidiary, net of cash acquired (see Note 4C)", "documentation": "Amount of acquisition of subsidiary, net of cash acquired.", "label": "Acquisition Of Subsidiary Net Of Cash Acquired" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r315" ] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r378" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r378" ] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r376" ] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability and right-of-use asset (in Dollars)", "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r62", "r117" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r328" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r328" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r328" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r328" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of ADSs used in calculation (in Shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r19" ] }, "ppbt_AdjustmentsForChangesInAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AdjustmentsForChangesInAssetsAndLiabilities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Changes in assets and liabilities, total", "documentation": "Adjustments for changes in assets and liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Changes In Assets And Liabilities" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in other current assets", "label": "Adjustments for decrease (increase) in other current assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } } }, "auth_ref": [ "r394" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Adjustments for depreciation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r394" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance income, net", "label": "Adjustments for finance income" } } }, "auth_ref": [ "r394" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss", "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss" } } }, "auth_ref": [ "r393" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in post-employment benefit liabilities", "label": "Adjustments for increase (decrease) in employee benefit liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r394" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in other payables", "label": "Adjustments for increase (decrease) in other operating payables" } } }, "auth_ref": [ "r392" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in trade payables", "label": "Adjustments for increase (decrease) in trade accounts payable" } } }, "auth_ref": [ "r392" ] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Total adjustments", "label": "Adjustments to reconcile profit (loss)" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments:", "label": "Adjustments to reconcile operating profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow", "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "verboseLabel": "Total share-based expense recognized", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r393" ] }, "ppbt_AdsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AdsMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/IntangibleAssetsDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ADS [Member]", "verboseLabel": "Ads [Member]", "label": "Ads Member" } } }, "auth_ref": [] }, "ppbt_AggregateGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AggregateGrossProceeds", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds (in Dollars)", "documentation": "The amount of aggregate gross proceeds.", "label": "Aggregate Gross Proceeds" } } }, "auth_ref": [] }, "ppbt_AggregateShareholdersOfImmunorizon": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AggregateShareholdersOfImmunorizon", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate shareholders of immunorizon (in Shares)", "documentation": "The aggregate shareholders of immunorizon.", "label": "Aggregate Shareholders Of Immunorizon" } } }, "auth_ref": [] }, "ppbt_AggregateUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AggregateUpfrontPayment", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate upfront payment", "documentation": "The amount of Aggregate upfront payment.", "label": "Aggregate Upfront Payment" } } }, "auth_ref": [] }, "ppbt_AggregateWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AggregateWarrantsShares", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate warrants shares (in Shares)", "documentation": "Aggregate warrants shares.", "label": "Aggregate Warrants Shares" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r369" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r278", "r289", "r305", "r340" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r281", "r292", "r308", "r343" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r370" ] }, "ppbt_AgreementLeaseAdditionalTerm": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AgreementLeaseAdditionalTerm", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement lease additional term", "documentation": "Agreement Lease Additional Term.", "label": "Agreement Lease Additional Term" } } }, "auth_ref": [] }, "ppbt_AgreementLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AgreementLeaseTerm", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement lease term", "documentation": "Agreement Lease Term.", "label": "Agreement Lease Term" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r328" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r335" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r282", "r293", "r309", "r335", "r344", "r348", "r356" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r354" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ppbt_AmericanDepositorySharesOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AmericanDepositorySharesOrdinaryShares", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails", "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American depository ordinary shares", "verboseLabel": "Ordinary shares (in Shares)", "documentation": "American depository shares ordinary shares.", "label": "American Depository Shares Ordinary Shares" } } }, "auth_ref": [] }, "ppbt_AmericanDepostioryShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "AmericanDepostioryShares", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American shares (in Shares)", "documentation": "American depository shares.", "label": "American Depostiory Shares" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax rate applicable", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r2", "r137" ] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r52", "r53", "r54", "r108", "r110", "r168", "r169", "r194" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable", "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable", "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r400", "r402" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable", "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r400", "r402" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r285" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r263", "r266", "r285" ] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r263", "r266", "r285" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r263", "r266", "r285" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r374" ] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Representative exchange rate", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r402" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r351" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r352" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r347" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r347" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r347" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r347" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r347" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r347" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r350" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r349" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r348" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r348" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per Share \u2013 USD (in Dollars per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r17", "r18" ] }, "ifrs-full_BasicEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsPerShareAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share information", "label": "Basic earnings per share [abstract]" } } }, "auth_ref": [] }, "ppbt_BiopharmaceuticalProductMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "BiopharmaceuticalProductMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biopharmaceutical Product [Member]", "label": "Biopharmaceutical Product Member" } } }, "auth_ref": [] }, "ppbt_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "BoardOfDirectorsMember", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors [Member]", "label": "Board Of Directors Member" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bear fixed interest, percentage", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r397" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of Range [Member]", "verboseLabel": "Down 2% [Member]", "netLabel": "Bottom of range [member]", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r34", "r56", "r72", "r89", "r133", "r230", "r231", "r397" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r266", "r285" ] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve from transactions with related parties", "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r404" ] }, "ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CapitalReserveFromTransactionsWithNon-ControllingInterest", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve from transactions with non- controlling interest", "documentation": "Capital reserve from transactions with non- controlling interest.", "label": "Capital Reserve From Transactions With Non- Controlling Interest" } } }, "auth_ref": [] }, "ppbt_CapitalReserveFromTransactionsWithNonControllingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CapitalReserveFromTransactionsWithNonControllingInterestMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve from transactions with Non- controlling interest", "documentation": "Capital reserve from transactions with Non-controlling interest.", "label": "Capital Reserve From Transactions With Non Controlling Interest Member" } } }, "auth_ref": [] }, "ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CapitalReserveFromTransactionsWithRelatedPartiesMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve from transactions with related parties", "label": "Capital Reserve From Transactions With Related Parties Member" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ConsolidatedCashFlow", "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at the beginning of the year", "periodEndLabel": "Cash and cash equivalents at end of the year", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Total cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r35", "r51", "r134", "r191" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "ppbt_CashAndCashEquivalentsAndDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CashAndCashEquivalentsAndDepositsMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and deposits [Member]", "label": "Cash And Cash Equivalents And Deposits Member" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in short term deposits", "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r390" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r29", "r36" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r29", "r36" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r29", "r36" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ppbt_CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CashandCashEquivalentsScheduleofCashandCashEquivalentsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/LeasesDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r144" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/LeasesDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r16", "r144" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r326" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Officers [Member]", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r323" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r321" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ppbt_ClassEPreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ClassEPreferredSharesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class E Preferred Shares [Member]", "label": "Class EPreferred Shares Member" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r23", "r55", "r64", "r119", "r147", "r170" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r21", "r55", "r64", "r119", "r147", "r170" ] }, "ifrs-full_ClassesOfCashPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfCashPaymentsAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Classes of cash payments from operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefits [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r100", "r101", "r103", "r104", "r165", "r167" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r100", "r101", "r103", "r104", "r165", "r167" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r27", "r150" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r27", "r150" ] }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOrdinarySharesAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of ordinary shares [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r17" ] }, "ifrs-full_ClassesOfOrdinarySharesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOrdinarySharesDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of ordinary shares [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r17" ] }, "ppbt_ClassesOfPreferredSharesAxis": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ClassesOfPreferredSharesAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Classes Of Preferred Shares [Axis]", "label": "Classes Of Preferred Shares Axis" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/GeneralDetails", "http://Purplebiotech.com/role/IntangibleAssetsDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r130", "r175", "r206" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/GeneralDetails", "http://Purplebiotech.com/role/IntangibleAssetsDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r130", "r175", "r206" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r327" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r327" ] }, "ppbt_CommitmentsAndContingentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CommitmentsAndContingentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities [Abstract]" } } }, "auth_ref": [] }, "ppbt_CommitmentsAndContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CommitmentsAndContingentLiabilitiesLineItems", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities [Line Items]" } } }, "auth_ref": [] }, "ppbt_CommitmentsandContingentLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CommitmentsandContingentLiabilitiesDetailsTable", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_CommonStockNoParValues": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CommonStockNoParValues", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock par value (in Dollars per share)", "documentation": "Common stock no par value.", "label": "Common Stock No Par Values" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r332" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r331" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r333" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r184" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r184" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total comprehensive loss for the year", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r38", "r40", "r48", "r146", "r153", "r180", "r210", "r229" ] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-controlling interests", "label": "Comprehensive income, attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r180", "r213" ] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterestsContinuingAndDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of the Information Relating to Non-Controlling Interests [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Owners of the Company", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r180", "r214" ] }, "ppbt_ConsolidatedStatementsOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ConsolidatedStatementsOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements Of Changes In Equity Abstract" } } }, "auth_ref": [] }, "ppbt_ConsultantPerShares": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ConsultantPerShares", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consultant per shares (in Dollars per share)", "documentation": "Represent the consultant per shares.", "label": "Consultant Per Shares" } } }, "auth_ref": [] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r266" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContainedFileInformationFileType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r240" ] }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentDomain", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "label": "Continuing involvement in derecognised financial assets by type of instrument [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used." } } }, "auth_ref": [ "r240" ] }, "ppbt_ConvertibleShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ConvertibleShares", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible shares (in Shares)", "documentation": "Convertible shares.", "label": "Convertible Shares" } } }, "auth_ref": [] }, "ppbt_ConvertibleWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ConvertibleWarrants", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible warrants (in Shares)", "documentation": "Convertible warrants.", "label": "Convertible Warrants" } } }, "auth_ref": [] }, "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "lang": { "en-us": { "role": { "label": "Basis of Preparation of the Consolidated Financial Statements [Abstract]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Risk [Member]", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r73", "r74", "r75", "r237" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Currency risk [Member]", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r73", "r74", "r75", "r76", "r106" ] }, "ppbt_CurrentAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CurrentAsset", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "documentation": "The value of Current assets.", "label": "Current Asset" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r44", "r197", "r229" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentGovernmentGrants", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Government authorities", "label": "Current government grants" } }, "en": { "role": { "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r404" ] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r404" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturity of lease liabilities", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r59" ] }, "ppbt_CurrentLiabilitie": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "CurrentLiabilitie", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "documentation": "Represent the current liabilities.", "label": "Current Liabilitie" } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r46", "r198", "r229" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other receivables", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r402" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]", "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r272", "r365" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]", "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r272", "r365" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]", "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r274", "r367" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]", "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r274", "r367" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]", "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r269", "r362" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]", "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r270", "r363" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r268", "r361" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r268", "r361" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r268", "r361" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]", "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r271", "r364" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Role of Management [Text Block]", "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r273", "r366" ] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r297", "r298", "r312" ] }, "ppbt_DepositaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DepositaryShares", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depositary shares", "documentation": "Depositary shares.", "label": "Depositary Shares" } } }, "auth_ref": [] }, "ppbt_DepositarysShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DepositarysShares", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depositary shares (in Shares)", "documentation": "Depositary shares.", "label": "Depositarys Shares" } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation expense, operating" } } }, "auth_ref": [ "r402" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation on right-to-use assets", "label": "Depreciation, right-of-use assets" } } }, "auth_ref": [ "r60", "r115" ] }, "ifrs-full_DerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialAssets", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt instrument and warrant", "label": "Derivative financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r404" ] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liability of warrants", "label": "Derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r404" ] }, "ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of consolidation", "documentation": "The description of the entity's accounting policy for basis of consolidation.", "label": "Description Of Accounting Policy For Basis Of Consolidation Policy Text Block" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Description of accounting policy for financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency transactions", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Description of accounting policy for impairment of assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of assets." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Financing income and expense", "label": "Description of accounting policy for interest income and expense [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income and expense arising from interest." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment transactions", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r403" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (%)", "verboseLabel": "Expected volatility", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r91" ] }, "ppbt_DescriptionOfOptionLifeShareOptionGranted": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DescriptionOfOptionLifeShareOptionGranted", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "documentation": "Expected term.", "label": "Description Of Option Life Share Option Granted" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected duration (years)", "label": "Option life, share options granted" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r91" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free rate interest rate (%)", "verboseLabel": "annual risk free interest", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r91" ] }, "ppbt_DiagnosticProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DiagnosticProductsMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diagnostic Products [Member]", "label": "Diagnostic Products Member" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per Share \u2013 USD (in Dollars per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r17", "r18" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "DirectorMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Directors [Member]", "label": "Director [Member]" } } }, "auth_ref": [] }, "ifrs-full_DirectorsRemunerationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DirectorsRemunerationExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Board member remuneration and insurance", "label": "Directors' remuneration expense, operating" } } }, "auth_ref": [ "r402" ] }, "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLessorExplanatory", "presentation": [ "http://Purplebiotech.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Profit or Loss", "label": "Disclosure of additional information about leasing activities for lessor [text block]" } }, "en": { "role": { "documentation": "The disclosure of additional information about leasing activities of a lessor." } } }, "auth_ref": [ "r65", "r120" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Preparation of the Consolidated Financial Statements", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://Purplebiotech.com/role/CashandCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting standards issued but not yet effective", "label": "Disclosure of changes in accounting policies [text block]" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://Purplebiotech.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share Capital", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r130", "r175", "r206" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable", "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Capital [Line Items]", "terseLabel": "Schedule of Changes in Share Capital [Line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingent liabilities", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r399" ] }, "ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/CashandCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "documentation": "The disclosure of detailed information about cash and cash equivalents.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalent Explanatory Table Text Block" } } }, "auth_ref": [] }, "ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Share Capital", "documentation": "Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block.", "label": "Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block" } } }, "auth_ref": [] }, "ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Contribution Plan in Respect of its Employees", "documentation": "The disclosure of detailed information about defined contribution plan.", "label": "Disclosure Of Detailed Information About Defined Contribution Plan Explanatory Table Text Block" } } }, "auth_ref": [] }, "ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Post-Employee Benefits", "documentation": "The disclosure of detailed information about employee benefits.", "label": "Disclosure Of Detailed Information About Employee Benefits Explanatory Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r27", "r150" ] }, "ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Information Relating to Non-Controlling Interests", "documentation": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock.", "label": "Disclosure Of Detailed Information About Noncontrolling Interests Table Text Block" } } }, "auth_ref": [] }, "ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Number of RSUs", "documentation": "The disclosure of detailed information about restricted stock unit.", "label": "Disclosure Of Detailed Information About Restricted Stock Unit Table Text Block" } } }, "auth_ref": [] }, "ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/OtherPayablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Payables", "documentation": "The disclosure of detailed information about of trade and other payables.", "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables", "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Data on Exchange Rates", "verboseLabel": "Schedule of Sensitivity Test to Possible Changes in Exchange Rate", "label": "Disclosure of effect of changes in foreign exchange rates [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r10" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://Purplebiotech.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expenses Recognized in the Consolidated Financial Statements", "label": "Disclosure of expenses by nature [text block]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Measurement", "label": "Disclosure of fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r55", "r170" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Instruments Measured at Fair Value", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfFinanceCostExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceCostExplanatory", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finance Expenses", "label": "Disclosure of finance cost [text block]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNet" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Expense (Income), net", "label": "Disclosure of finance income (cost) [text block]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfFinanceIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExplanatory", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finance Income", "label": "Disclosure of finance income [text block]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://Purplebiotech.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable", "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Sensitivity Test to Possible Changes in Exchange Rate [Line Items]", "terseLabel": "Financial Instruments [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "presentation": [ "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Sales, General and Administrative Expenses", "label": "Disclosure of general and administrative expense [text block]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://Purplebiotech.com/role/General" ], "lang": { "en-us": { "role": { "terseLabel": "General", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r125", "r187" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r3" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions were Used", "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r92" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recorded Expenses", "label": "Disclosure of information about key management personnel [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract", "lang": { "en-us": { "role": { "label": "Material Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://Purplebiotech.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Disclosure of leases [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r68", "r69" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://Purplebiotech.com/role/MaterialAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Material Accounting Policies", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r135", "r177", "r185" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "presentation": [ "http://Purplebiotech.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturity Analysis of the Company's Lease Liabilities", "label": "Disclosure of maturity analysis of operating lease payments [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r67", "r124" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturity Analysis of the Company's Lease Liabilities [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Number and Weighted Average Exercise Prices of Share Options", "label": "Disclosure of number and weighted average exercise prices of share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r87", "r160" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://Purplebiotech.com/role/OtherCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Disclosure of other current assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r399" ] }, "ppbt_DisclosureOfOtherCurrentAssettextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfOtherCurrentAssettextBlock", "presentation": [ "http://Purplebiotech.com/role/OtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "documentation": "The disclosure of other current assets.", "label": "Disclosure Of Other Current Assettext Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "presentation": [ "http://Purplebiotech.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amounts of Right-to-Use Assets", "label": "Disclosure of quantitative information about right-of-use assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r64", "r119" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Carrying Amounts of Right-to-Use Assets [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Number and Weighted Average Exercise Prices of Share Options [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r389" ] }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://Purplebiotech.com/role/ResearchandDevelopmentExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Disclosure of research and development expense [text block]" } } }, "auth_ref": [ "r399" ] }, "ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Research and Development Expenses", "documentation": "No definition available.", "label": "Disclosure Of Research And Development Expenses Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReservesWithinEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReservesWithinEquityLineItems", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://Purplebiotech.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r131", "r176", "r207" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangements", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r80" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangements [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Schedule of Expenses Recognized in the Consolidated Financial Statements [Line Items]", "verboseLabel": "Share-Based Payment Arrangements [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://Purplebiotech.com/role/OtherPayables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Payables", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r399" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties" ], "lang": { "en-us": { "role": { "terseLabel": "Transactions and Balances with Related Parties", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r15", "r143" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Recorded Expenses [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales, General and Administrative Expenses", "documentation": "Disclosures of general and administrative expenses explanatory.", "label": "Disclosures Of Detailed Information About General And Administrative Expenses Explanatory Table Text Block" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r297", "r298", "r312" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r266" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r263", "r266", "r285" ] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentCopyrightInformation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentCreationDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentEffectiveDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r263", "r266", "r285", "r336" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r263", "r266", "r285", "r336" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationDocumentAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r264" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r252" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r266" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r266" ] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentSubtitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentSynopsis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r313" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentVersion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r255" ] }, "ppbt_DownRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "DownRangeOneMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Down 5% [Member]", "label": "Down Range One Member" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r325" ] }, "ppbt_EUROMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EUROMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "EURO [Member]", "label": "EUROMember" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of translation adjustments on cash and cash equivalents", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r31", "r32" ] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r382" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r382" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r383" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r382" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r383" ] }, "ppbt_EffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EffectiveTaxRate", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "documentation": "Effective tax rate.", "label": "Effective Tax Rate" } } }, "auth_ref": [] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r381" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r383" ] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r385" ] }, "ppbt_EmployeeBenefitBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EmployeeBenefitBonus", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonuses expenses", "documentation": "Employee benefit bonus.", "label": "Employee Benefit Bonus" } } }, "auth_ref": [] }, "ppbt_EmployeeBenefitsLiabilityDueGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EmployeeBenefitsLiabilityDueGrants", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits liability due grants", "documentation": "Employee benefits liability due grants.", "label": "Employee Benefits Liability Due Grants" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitiesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r254" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r258" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r254" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityContactPersonnelLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r254" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r384" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r254" ] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityHomeCountryISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r373" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r372" ] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityLegalForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingForeign", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingParValuePerShare", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingPrimary", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingSecurityTradingCurrency", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityNumberOfEmployees", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r285" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r254" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r254" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r254" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r254" ] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r375" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r319" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r368" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r368" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r368" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r37", "r39", "r52", "r53", "r54", "r145", "r152", "r168", "r169", "r179", "r194", "r201" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r194" ] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Equity attributable to owners of the Company", "label": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Equity attributable to owners of parent [member]" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r184" ] }, "ppbt_EquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EquityDetailsTable", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_EquityMethodInvestmentsOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EquityMethodInvestmentsOwnershipPercentage", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Direct ownership of equity", "documentation": "Direct ownership of equity.", "label": "Equity Method Investments Ownership Percentage" } } }, "auth_ref": [] }, "ppbt_EquityScheduleofChangesinShareCapitalDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EquityScheduleofChangesinShareCapitalDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" ], "lang": { "en-us": { "role": { "label": "Equity - Schedule of Changes in Share Capital (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_EquityScheduleofShareCapitalDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "EquityScheduleofShareCapitalDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "label": "Equity - Schedule of Share Capital (Details) [Table]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r329" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r278", "r289", "r305", "r340" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r275", "r286", "r302", "r337" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExchangeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r335" ] }, "ppbt_ExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ExerciseOfWarrantsEquity", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants fair value (in Dollars)", "documentation": "Represent the exercise of warrants equity.", "label": "Exercise Of Warrants Equity" } } }, "auth_ref": [] }, "ppbt_ExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ExercisePeriod", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable period", "documentation": "It represents exercise period.", "label": "Exercise Period" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price - USD (in Dollars per share)", "verboseLabel": "Exercise price (in Dollars per share)", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r91" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r380" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r380" ] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (%)", "label": "Expected dividend as percentage, share options granted" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r91" ] }, "ppbt_ExpectedDividendAsPercentageShareOptionsdividendYield": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ExpectedDividendAsPercentageShareOptionsdividendYield", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "dividend yield", "documentation": "Percentage of dividend yield", "label": "Expected Dividend As Percentage Share Optionsdividend Yield" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Expense from share-based payment transactions with employees, operating" } } }, "auth_ref": [ "r402" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Board member share-based payments", "label": "Expense from share-based payment transactions with parties other than employees" } } }, "auth_ref": [ "r402" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "ppbt_FairValueMeasurementBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FairValueMeasurementBalance", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value measurement balance.", "label": "Fair Value Measurement Balance" } } }, "auth_ref": [] }, "ppbt_FairValueMeasurementExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FairValueMeasurementExercise", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise", "documentation": "Represent the fair value of exercise.", "label": "Fair Value Measurement Exercise" } } }, "auth_ref": [] }, "ppbt_FairValueMeasurementIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FairValueMeasurementIssuance", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance", "documentation": "Fair value measurement issuance.", "label": "Fair Value Measurement Issuance" } } }, "auth_ref": [] }, "ppbt_FairValueMeasurementIssuanceProceed": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FairValueMeasurementIssuanceProceed", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Proceed", "documentation": "Fair value measurement proceed.", "label": "Fair Value Measurement Issuance Proceed" } } }, "auth_ref": [] }, "ppbt_FairValueMeasurementRevaluation": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FairValueMeasurementRevaluation", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revaluation", "documentation": "Fair value measurement revaluation.", "label": "Fair Value Measurement Revaluation" } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FeeAndCommissionExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": { "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fees and interest expense", "label": "Fee and commission expense, operating" } } }, "auth_ref": [ "r408" ] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Finance expenses", "label": "Finance costs" } } }, "auth_ref": [ "r215" ] }, "ppbt_FinanceExpenseIncomeNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinanceExpenseIncomeNetAbstract", "lang": { "en-us": { "role": { "label": "Finance Expense (Income), Net [Abstract]" } } }, "auth_ref": [] }, "ppbt_FinanceExpenseIncomeNetTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinanceExpenseIncomeNetTablesLineItems", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Expense (Income), Net [Abstract]", "label": "Finance Expense Income Net Tables Line Items" } } }, "auth_ref": [] }, "ppbt_FinanceExpenseIncomeNetTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinanceExpenseIncomeNetTablesTable", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" ], "lang": { "en-us": { "role": { "label": "Finance Expense (Income), Net (Tables) [Table]" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance income", "label": "Finance income" } } }, "auth_ref": [ "r408" ] }, "ppbt_FinanceIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinanceIncomeAbstract", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income", "label": "Finance Income Abstract" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Finance income, net", "label": "Finance income (cost)" } } }, "auth_ref": [ "r408" ] }, "ppbt_FinancialAssetAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialAssetAndLiabilitiesAbstract", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Financial asset and liabilities", "label": "Financial Asset And Liabilities Abstract" } } }, "auth_ref": [] }, "ppbt_FinancialAssetConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialAssetConvertibleNoteMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Financial asset- convertible note [Member]", "label": "Financial Asset Convertible Note Member" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsLineItems", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Line Items]" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsScheduleofDetailsRegardingFairValueMeasurementDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "label": "Financial Instruments - Schedule of Details Regarding Fair Value Measurement (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsScheduleofFairValueMeasurementDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "label": "Financial Instruments - Schedule of Fair Value Measurement (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsScheduleofFinancialInstrumentsMeasuredatFairValueDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsScheduleofSensitivityTesttoPossibleChangesinExchangeRateDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "label": "Financial Instruments - Schedule of Sensitivity Test to Possible Changes in Exchange Rate (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_FinancialInstrumentsTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialInstrumentsTablesTable", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Financial Instruments (Tables) [Table]" } } }, "auth_ref": [] }, "ppbt_FinancialLiabilityWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FinancialLiabilityWarrantMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDetailsRegardingFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liability- warrant [Member]", "label": "Financial Liability Warrant Member" } } }, "auth_ref": [] }, "ppbt_ForTheYearEndedDecember312024Abstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ForTheYearEndedDecember312024Abstract", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "For the year ended December 31, 2024", "label": "For The Year Ended December312024 Abstract" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": { "parentTag": "ifrs-full_OtherFinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Income from exchange rate differences, net", "label": "Foreign exchange gain" } } }, "auth_ref": [ "r8", "r140", "r186" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": { "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from exchange rate differences, net", "label": "Foreign exchange loss" } } }, "auth_ref": [ "r8", "r140", "r186" ] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Data on Exchange Rates [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r282", "r293", "r309", "r344" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r282", "r293", "r309", "r344" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r282", "r293", "r309", "r344" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r282", "r293", "r309", "r344" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r282", "r293", "r309", "r344" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "FormerAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r265", "r296" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "FormerFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r324" ] }, "ppbt_FunctionalCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FunctionalCurrency", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Functional currency", "documentation": "The amount of functional currency.", "label": "Functional Currency" } } }, "auth_ref": [] }, "ppbt_FundsRaisedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FundsRaisedAmount", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company funds raised (in Dollars)", "documentation": "Funds raised amount.", "label": "Funds Raised Amount" } } }, "auth_ref": [] }, "ppbt_FundsRaisedshares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "FundsRaisedshares", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funds raised amount", "documentation": "Funds raised amount.", "label": "Funds Raisedshares" } } }, "auth_ref": [] }, "ppbt_GainLossOnWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "GainLossOnWarrants", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants generated", "documentation": "The amount of gain loss warrants.", "label": "Gain Loss On Warrants" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrants", "label": "Gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r408" ] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": { "parentTag": "ifrs-full_OtherFinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in fair value of finance instruments (see Note 18B2)", "label": "Gains on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r408" ] }, "ifrs-full_GainsOnLitigationSettlements": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnLitigationSettlements", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains on litigation settlements", "label": "Gains on litigation settlements, operating" } } }, "auth_ref": [ "r218" ] }, "ppbt_GeneralAndAdministrativeExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "GeneralAndAdministrativeExpensesOther", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.", "label": "General And Administrative Expenses Other" } } }, "auth_ref": [] }, "ppbt_GeneralDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "GeneralDetailsTable", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "General (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_GeneralLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "GeneralLineItems", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "General [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r111", "r221", "r232", "r234", "r243" ] }, "ppbt_GovernmentAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "GovernmentAuthorities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Government authorities", "documentation": "Government authorities.", "label": "Government Authorities" } } }, "auth_ref": [] }, "ppbt_IPRDRelatedToFamewaveSee5BBelowMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IPRDRelatedToFamewaveSee5BBelowMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D related to Famewave (see 4B below) [Member]", "label": "IPRDRelated To Famewave See5 BBelow Member" } } }, "auth_ref": [] }, "ppbt_IPRDRelatedToImmunorizonSee5CBelowMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IPRDRelatedToImmunorizonSee5CBelowMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D related to Immunorizon (see 4C below) [Member]", "label": "IPRDRelated To Immunorizon See5 CBelow Member" } } }, "auth_ref": [] }, "ppbt_IPRDRelatedToPurpleGmbHMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IPRDRelatedToPurpleGmbHMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D related to Purple GmbH (see 4D below) [Member]", "label": "IPRDRelated To Purple Gmb HMember" } } }, "auth_ref": [] }, "ppbt_IPRDRelatedToTryNovosee5ABelowMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IPRDRelatedToTryNovosee5ABelowMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D related to TyrNovo (see 4A below) [Member]", "label": "IPRDRelated To Try Novosee5 ABelow Member" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r263", "r266", "r285" ] }, "ifrs-full_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLoss", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss", "label": "Impairment loss" } }, "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r22", "r23" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or Loss [Abstract]" } } }, "auth_ref": [] }, "ppbt_IncomelossFromChangeInExchangeRateDown": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IncomelossFromChangeInExchangeRateDown", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from change in exchange rate", "documentation": "Amount of income (loss) from change in exchange rate.", "label": "Incomeloss From Change In Exchange Rate Down" } } }, "auth_ref": [] }, "ppbt_IncomelossFromChangeInExchangeRateUp": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IncomelossFromChangeInExchangeRateUp", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from change in exchange rate", "documentation": "Amount of income (loss) from change in exchange rate.", "label": "Incomeloss From Change In Exchange Rate Up" } } }, "auth_ref": [] }, "ppbt_IncomelossValue": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IncomelossValue", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) value", "documentation": "Income loss value.", "label": "Incomeloss Value" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r35", "r134" ] }, "ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAcquisitionOfSubsidiary", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "ADS issued in connection with the purchase of a subsidiary (see Note 4C)", "label": "Increase (decrease) through acquisition of subsidiary, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r401" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant inducement transaction", "label": "Increase (decrease) through exercise of warrants, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r401" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r183" ] }, "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransactionsWithOwners", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Total transactions with owners of the Company", "label": "Increase (decrease) through transactions with owners, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from transactions with owners." } } }, "auth_ref": [ "r401" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r282", "r293", "r309", "r335", "r344", "r348", "r356" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r354" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r267", "r360" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r267", "r360" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r267", "r360" ] }, "ifrs-full_InsuranceContractsIssuedThatAreAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InsuranceContractsIssuedThatAreAssets", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prospectus amount (in Dollars)", "label": "Insurance contracts issued that are assets" } }, "en": { "role": { "documentation": "The amount of insurance contracts issued that are assets. [Refer: Assets; Insurance contracts issued [member]]" } } }, "auth_ref": [ "r79", "r190" ] }, "ppbt_IntangibleAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IntangibleAssetsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_IntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IntangibleAssetsLineItems", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "verboseLabel": "Total intangible assets", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r26", "r149", "r189" ] }, "ppbt_IntangibleAssetsRecoverableAmountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IntangibleAssetsRecoverableAmountPercentage", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets recoverable amount percentage", "documentation": "Intangible assets recoverable amount percentage.", "label": "Intangible Assets Recoverable Amount Percentage" } } }, "auth_ref": [] }, "ppbt_IntangibleAssetsScheduleofIntangibleAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IntangibleAssetsScheduleofIntangibleAssetsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofIntangibleAssetsTable" ], "lang": { "en-us": { "role": { "label": "Intangible Assets - Schedule of Intangible Assets (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_IntangibleAssetsTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IntangibleAssetsTablesLineItems", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Abstract]", "label": "Intangible Assets Tables Line Items" } } }, "auth_ref": [] }, "ppbt_IntangibleAssetsTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IntangibleAssetsTablesTable", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Intangible Assets (Tables) [Table]" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAmountsRecognizedinProfitorLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses on lease liability", "label": "Interest expense on lease liabilities, financing" } } }, "auth_ref": [ "r61", "r116" ] }, "ifrs-full_InterestIncomeOnDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnDeposits", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": { "parentTag": "ifrs-full_OtherFinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income from deposits", "label": "Interest income on deposits" } } }, "auth_ref": [ "r402" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r33" ] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r298", "r299", "r300", "r301" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r314" ] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r314" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r314" ] }, "ppbt_IssuanceExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IssuanceExpenses", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": { "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance expenses (see note 9D)", "documentation": "The amount of issuance expenses.", "label": "Issuance Expenses" } } }, "auth_ref": [] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note amount", "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r401" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital, no par value", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r245", "r249" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r184" ] }, "ppbt_IssuesOfEquity": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "IssuesOfEquity", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of equity", "documentation": "Issue of equity.", "label": "Issues Of Equity" } } }, "auth_ref": [] }, "ppbt_ItemsThatWillBeTransferredToProfitOrLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ItemsThatWillBeTransferredToProfitOrLossAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Items that will be transferred to profit or loss:", "label": "Items That Will Be Transferred To Profit Or Loss Abstract" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Key management personnel compensation, operating" } } }, "auth_ref": [ "r14", "r142" ] }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefits", "label": "Key management personnel compensation, post-employment benefits" } } }, "auth_ref": [ "r12" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share based payments", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r13" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short - term", "label": "Key management personnel compensation, short-term employee benefits, operating" } } }, "auth_ref": [ "r11" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "One to two years [Member]", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r66", "r67", "r78", "r239", "r242", "r402" ] }, "ppbt_LeaseAgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LeaseAgreementOneMember", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Agreement One [Member]", "label": "Lease Agreement One Member" } } }, "auth_ref": [] }, "ppbt_LeaseAgreementsTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LeaseAgreementsTwoMember", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Agreements Two [Member]", "label": "Lease Agreements Two Member" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable", "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Extension of a new lease agreement", "verboseLabel": "Total", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r59" ] }, "ifrs-full_LeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Amounts Recognized in Profit or Loss [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_LeaseReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseReceivablesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Office lease [Member]", "label": "Lease receivables [member]" } }, "en": { "role": { "documentation": "This member stands for receivables related to leases." } } }, "auth_ref": [ "r99", "r102", "r164", "r166", "r238" ] }, "ppbt_LeasesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LeasesDetailsTable", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_LeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LeasesLineItems", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Leases [Line Items]" } } }, "auth_ref": [] }, "ppbt_LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LeasesScheduleofCarryingAmountsofRighttoUseAssetsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" ], "lang": { "en-us": { "role": { "label": "Leases - Schedule of Carrying Amounts of Right-to-Use Assets (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LeasesScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Leases - Schedule of Maturity Analysis of the Company's Lease Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityIdentifier", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r5", "r24", "r25", "r53", "r148", "r169" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r24", "r25", "r53", "r148", "r169" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r24", "r25", "r53", "r148", "r169" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r53", "r169" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinancialInstrumentsMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r5", "r53", "r169" ] }, "ifrs-full_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r132", "r227" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r132", "r227" ] }, "ifrs-full_LicenceFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LicenceFeeIncome", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual license fee (in Dollars)", "label": "Licence fee income, operating" } } }, "auth_ref": [ "r402" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ppbt_LongTermMilestonesAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "LongTermMilestonesAggregateAmount", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term milestones aggregate amount", "documentation": "The amount of long term Milestones aggregate amount.", "label": "Long Term Milestones Aggregate Amount" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r57", "r66", "r67", "r70", "r71", "r72", "r78", "r96", "r105", "r113", "r114", "r122", "r124", "r163", "r196", "r222", "r239" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r57", "r66", "r67", "r70", "r71", "r72", "r78", "r96", "r113", "r114", "r122", "r124", "r163", "r196", "r222", "r239", "r241" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r327" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r327" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r347" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r355" ] }, "ppbt_NISMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NISMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "NIS [Member]", "label": "NISMember" } } }, "auth_ref": [] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NameChangeEventDateAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NameChangeEventLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NameChangeEventTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r328" ] }, "ppbt_NetAssetsAttributableToNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NetAssetsAttributableToNonControllingInterest", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets attributable to non-controlling interests", "documentation": "The value of Mount of net assets attributable to non-controlling interest.", "label": "Net Assets Attributable To Non Controlling Interest" } } }, "auth_ref": [] }, "ppbt_NetAssetsAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NetAssetsAttributableToNoncontrollingInterests", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss allocated to non-controlling interests", "documentation": "The amount of net assets attributable to non-controlling interests.", "label": "Net Assets Attributable To Noncontrolling Interests" } } }, "auth_ref": [] }, "ifrs-full_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetAssetsLiabilities", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets", "label": "Assets (liabilities)" } }, "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } } }, "auth_ref": [ "r228", "r402" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "ppbt_NetPlacementAgentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NetPlacementAgentFees", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net placement agent fees (in Dollars)", "documentation": "The amount of net placement agent fees.", "label": "Net Placement Agent Fees" } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r298", "r299", "r300", "r301" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r379" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r379" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r327" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r282", "r293", "r309", "r335", "r344" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r318" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r317" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r335" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r355" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r355" ] }, "ppbt_NonVotingSeniorPreferredShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NonVotingSeniorPreferredShares", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-voting senior preferred shares", "documentation": "Non-voting senior preferred shares.", "label": "Non Voting Senior Preferred Shares" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/GeneralDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r136" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r136" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r41", "r43", "r192" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Non- controlling interests", "verboseLabel": "Total", "label": "Non-controlling interests [member]" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r184" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total non - current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r45", "r197", "r229" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total non - current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r47", "r198", "r229" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefit liabilities", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r178", "r200" ] }, "ifrs-full_NoncurrentWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentWarrantLiability", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Non-current warrant liability" } }, "en": { "role": { "documentation": "The amount of non-current warrant liabilities. [Refer: Warrant liability]" } } }, "auth_ref": [ "r404" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofMaturityAnalysisoftheCompanysLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Less than one year\t[Member]", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r66", "r67", "r78", "r121", "r123", "r195", "r239", "r242" ] }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotesAndOtherExplanatoryInformationAbstract", "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "auth_ref": [] }, "ppbt_NumberOfExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NumberOfExerciseOfWarrants", "presentation": [ "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants and prefunded warrants", "documentation": "Exercise of warrants.", "label": "Number Of Exercise Of Warrants" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted during the year", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r93", "r396" ] }, "ppbt_NumberOfIssuanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NumberOfIssuanceShares", "presentation": [ "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ADSs", "documentation": "The number of issuance shares.", "label": "Number Of Issuance Shares" } } }, "auth_ref": [] }, "ppbt_NumberOfNonTradableWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NumberOfNonTradableWarrants", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate shares", "documentation": "Number Of Non Tradable Warrants.", "label": "Number Of Non Tradable Warrants" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested during the year", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r396" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited during the year", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r396" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberofRSUsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at January 1", "periodEndLabel": "Outstanding at December 31", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r396" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options, Outstanding beginning balance", "periodEndLabel": "Number of options, Outstanding ending balance", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r81", "r85", "r89", "r154", "r158" ] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options, Exercisable", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r86", "r159" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, Expired and forfeited during the year", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r83", "r156" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options, Granted during the year", "verboseLabel": "Granted shares", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r82", "r155" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Authorized", "label": "Number of shares authorised" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r126", "r171", "r202" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Issued as at January 1", "periodEndLabel": "Issued as at December 31", "terseLabel": "Shares issued", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r401" ] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Issued and paid-in", "label": "Number of shares issued and fully paid" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r127", "r172", "r203" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized share capital", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r129", "r174", "r205" ] }, "ppbt_NumberOfVestingOfRsus": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "NumberOfVestingOfRsus", "presentation": [ "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of RSUs", "documentation": "Number of vesting of RSU.", "label": "Number Of Vesting Of Rsus" } } }, "auth_ref": [] }, "ppbt_OfferingPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OfferingPricePerShare", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering price per share (in Dollars per share)", "documentation": "Price of offering price per share.", "label": "Offering Price Per Share" } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OfficerMember", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officer [Member]", "label": "Officer [Member]" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating expense, operating" } } }, "auth_ref": [ "r408" ] }, "ppbt_OptionExerciseOrdinaryShare": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OptionExerciseOrdinaryShare", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option exercise ordinary share (in Shares)", "documentation": "Option exercise ordinary share.", "label": "Option Exercise Ordinary Share" } } }, "auth_ref": [] }, "ppbt_OrdinaryShareMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OrdinaryShareMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Share [Member]", "label": "Ordinary Share Member" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares [Member]", "verboseLabel": "Ordinary shares [member]", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r407" ] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive profit (loss) for the year", "label": "Other comprehensive income" } } }, "auth_ref": [ "r50", "r182", "r209", "r216" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxCashFlowHedges", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (profit) from cash flow hedges", "label": "Other comprehensive income, before tax, cash flow hedges" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income, before tax]" } } }, "auth_ref": [ "r199", "r217" ] }, "srt_OtherCurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "OtherCurrencyMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Balance in other currencies [Member]", "label": "Other Currency [Member]" } } }, "auth_ref": [] }, "ppbt_OtherCurrentAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OtherCurrentAssetMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets [Member]", "label": "Other Current Asset Member" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total other current assets", "terseLabel": "Other current assets", "label": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r404" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 }, "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total other payables", "terseLabel": "Other payables", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r404" ] }, "ppbt_OtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OtherExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": { "parentTag": "ifrs-full_OtherFinanceIncome", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "documentation": "Other.", "label": "Other Expense" } } }, "auth_ref": [] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance expenses", "terseLabel": "Issuance expenses (in Dollars)", "label": "Other expenses, by nature" } } }, "auth_ref": [ "r219", "r246" ] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceIncomeTable" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total finance income", "label": "Other finance income" } } }, "auth_ref": [ "r402" ] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r404" ] }, "ppbt_OtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OtherPayablesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables [Member]", "label": "Other Payables Member" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r327" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r266" ] }, "ppbt_OtherfinancialCost": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "OtherfinancialCost", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable": { "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "documentation": "Other.", "label": "Otherfinancial Cost" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r280", "r291", "r307", "r342" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r283", "r294", "r310", "r345" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r283", "r294", "r310", "r345" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public offering issued price (in Dollars per share)", "verboseLabel": "Exercise price per share (in Dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r128", "r173", "r204" ] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ParentEntityLegalName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r316" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "ADS issuance expenses paid", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r391" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of lease liability", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r226" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r326" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r326" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r318" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r335" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r328" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r317" ] }, "ppbt_PercentageOfCapacityOfAnAdvisor": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PercentageOfCapacityOfAnAdvisor", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of capacity of an advisor", "documentation": "Percentage of capacity of an advisor.", "label": "Percentage Of Capacity Of An Advisor" } } }, "auth_ref": [] }, "ppbt_PercentageOfContractToAcquire": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PercentageOfContractToAcquire", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract to acquire, percentage", "documentation": "Contract to acquire, percentage.", "label": "Percentage Of Contract To Acquire" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfEntitysRevenue": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfEntitysRevenue", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual interest rate of revenues", "label": "Percentage of entity's revenue" } } }, "auth_ref": [ "r398" ] }, "ppbt_PercentageOfExchangeRate": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PercentageOfExchangeRate", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDataonExchangeRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Representative exchange rate, percentage", "documentation": "Percentage of exchange rate.", "label": "Percentage Of Exchange Rate" } } }, "auth_ref": [] }, "ppbt_PercentageOfReceiveExitFee": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PercentageOfReceiveExitFee", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of exit fee", "documentation": "Percentage of receive exit fee.", "label": "Percentage Of Receive Exit Fee" } } }, "auth_ref": [] }, "ppbt_PercentageOfSublicenseConsideration": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PercentageOfSublicenseConsideration", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sublicense consideration", "documentation": "Percentage of sublicense consideration.", "label": "Percentage Of Sublicense Consideration" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interest", "label": "Percentage of voting equity interests acquired" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r94", "r162" ] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PhoneFaxNumberDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r319" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r371" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r318" ] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r252" ] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r252" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofDefinedContributionPlaninRespectofitsEmployeesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount recognized as expense in respect of defined contribution plan", "label": "Post-employment benefit expense, defined contribution plans" } } }, "auth_ref": [ "r6", "r139" ] }, "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseInProfitOrLoss", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefit liabilities", "label": "Post-employment benefit expense in profit or loss" } } }, "auth_ref": [ "r386" ] }, "ppbt_PostemploymentBenefitLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PostemploymentBenefitLiabilitiesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefit liabilities [Member]", "label": "Postemployment Benefit Liabilities Member" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r259" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r261" ] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r252" ] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r252" ] }, "ppbt_PreFundExercisePriceWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PreFundExercisePriceWarrants", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Funded exercise price warrants (in Dollars per share)", "documentation": "The price of pre fund warrants.", "label": "Pre Fund Exercise Price Warrants" } } }, "auth_ref": [] }, "ppbt_PreFundedWarant": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PreFundedWarant", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre funded warrant (in Dollars per share)", "documentation": "Price of pre funded warrant.", "label": "Pre Funded Warant" } } }, "auth_ref": [] }, "ifrs-full_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreferenceSharesMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Shares [Member]", "label": "Preference shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r407" ] }, "ppbt_PreferredClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PreferredClassCMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class C Preferred Shares [Member]", "label": "Preferred Class CMember" } } }, "auth_ref": [] }, "ppbt_PreferredClassDMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PreferredClassDMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class D Preferred Shares [Member]", "label": "Preferred Class DMember" } } }, "auth_ref": [] }, "ppbt_PreferredShareClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PreferredShareClassBMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Preferred Shares [Member]", "label": "Preferred Share Class BMember" } } }, "auth_ref": [] }, "ppbt_PreferredShareClassMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PreferredShareClassMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Preferred Shares [Member]", "label": "Preferred Share Class Member" } } }, "auth_ref": [] }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PresentationOfLeasesForLesseeAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "ppbt_PrivateAndPublicFinancingTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PrivateAndPublicFinancingTotal", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net of issuance expenses (in Dollars)", "documentation": "Represent the amount of private and public financing value.", "label": "Private And Public Financing Total" } } }, "auth_ref": [] }, "ppbt_PrivatePlacementsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PrivatePlacementsMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "label": "Private Placements Member" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from warrant inducement transaction", "verboseLabel": "Warrant exercised", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r391" ] }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingOtherEquityInstruments", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of warrants and prefunded warrants", "label": "Proceeds from issuing other equity instruments" } }, "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of ADSs", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceed from other investments", "label": "Proceeds from sales of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r224" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other professional fees", "verboseLabel": "Placement agent fees and other offering related expenses (in Dollars)", "label": "Professional fees expense" } } }, "auth_ref": [ "r402" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Loss for the year", "terseLabel": "Loss for the year", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r38", "r40", "r108", "r109", "r146", "r153", "r181", "r208", "r229", "r233" ] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss attributable to:", "label": "Profit (loss), attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-controlling interests", "label": "Profit (loss), attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r42", "r211" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTableAlt0": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Owners of the Company", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss for the year", "label": "Profit (loss) from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]" } } }, "auth_ref": [ "r49", "r108", "r109", "r208" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ScheduleoftheInformationRelatingtoNonControllingInterestsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss for the year", "label": "Profit (loss) from continuing operations attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]" } } }, "auth_ref": [ "r235", "r236" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets, net", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r4", "r138", "r188" ] }, "ppbt_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PublicOfferingMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public offering [Member]", "verboseLabel": "Public Offering [Member]", "label": "Public Offering Member" } } }, "auth_ref": [] }, "ppbt_PurchaseOfCommonStockAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "PurchaseOfCommonStockAndWarrants", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase shares", "documentation": "The company granted representative of the non traded warrants to purchase of common stock.", "label": "Purchase Of Common Stock And Warrants" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of fixed assets", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r223" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r316" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r316" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r34", "r56", "r72", "r89", "r133", "r230", "r231", "r397" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r34", "r56", "r72", "r89", "r133", "r230", "r231", "r397" ] }, "ppbt_RangesAxis": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "RangesAxis", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges [Axis]", "label": "Ranges Axis" } } }, "auth_ref": [] }, "ppbt_RangesDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "RangesDomainDomain", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "RangesDomain [Domain]" } } }, "auth_ref": [] }, "ppbt_ReceiptsOnAccountOfWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ReceiptsOnAccountOfWarrantsMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts on account of warrants", "label": "Receipts On Account Of Warrants Member" } } }, "auth_ref": [] }, "ppbt_ReceiptsOnAccountsOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ReceiptsOnAccountsOfWarrant", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts on account of warrants", "documentation": "The amount of receipts on account of warrants.", "label": "Receipts On Accounts Of Warrant" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r275", "r286", "r302", "r337" ] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "RegistrationStatementAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": [ "r252" ] }, "ppbt_RehovotMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "RehovotMember", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rehovot [Member]", "label": "Rehovot Member" } } }, "auth_ref": [] }, "ppbt_ReimbursementOfLegalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ReimbursementOfLegalFeesExpense", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Reimbursement of legal fees", "documentation": "Reimbursement of legal fees.", "label": "Reimbursement Of Legal Fees Expense" } } }, "auth_ref": [] }, "ifrs-full_RentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RentalExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Maintenance expenses", "label": "Rental expense, operating" } } }, "auth_ref": [ "r408" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r28", "r151" ] }, "ppbt_ResearchAndDevelopmentExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ResearchAndDevelopmentExpensesAbstract", "lang": { "en-us": { "role": { "label": "Research and Development Expenses [Abstract]" } } }, "auth_ref": [] }, "ppbt_ResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ResearchAndDevelopmentExpensesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses [Member]", "label": "Research And Development Expenses Member" } } }, "auth_ref": [] }, "ppbt_ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ResearchandDevelopmentExpensesScheduleofResearchandDevelopmentExpensesDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses - Schedule of Research and Development Expenses (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfCashFlowHedgesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfCashFlowHedgesMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve from hedging", "label": "Reserve of cash flow hedges [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the accumulated portion of gain (loss) on a hedging instrument that is determined to be an effective hedge for cash flow hedges. [Refer: Cash flow hedges [member]]" } } }, "auth_ref": [ "r112", "r247" ] }, "ifrs-full_ReserveOfSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPayments", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve for share-based payments", "label": "Reserve of share-based payments" } }, "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } } }, "auth_ref": [ "r405" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve for share- based payments", "label": "Reserve of share-based payments [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r247" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r276", "r287", "r303", "r338" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r277", "r288", "r304", "r339" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r284", "r295", "r311", "r346" ] }, "ifrs-full_RestrictedShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedShareUnitsMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs Granted [Member]", "verboseLabel": "Restricted share units [Member]", "netLabel": "Restricted share units [member]", "label": "Restricted share units [member]" } }, "en": { "role": { "documentation": "This member stands for restricted share units." } } }, "auth_ref": [ "r388" ] }, "ppbt_RetainedEarning": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "RetainedEarning", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings (in Dollars)", "documentation": "Amount of retained earning.", "label": "Retained Earning" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated loss", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r245", "r249", "r250" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated loss", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r184", "r247" ] }, "ifrs-full_RevenueFromRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromRoyalties", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty payable", "label": "Royalty income, operating" } } }, "auth_ref": [ "r402" ] }, "ppbt_ReverseRatio": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ReverseRatio", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse ratio", "documentation": "Reverse Ratio.", "label": "Reverse Ratio" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofCarryingAmountsofRighttoUseAssetsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "terseLabel": "Right to use assets", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r58", "r63", "r118" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r355" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r355" ] }, "ppbt_SalariesWagesAndRelatedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SalariesWagesAndRelatedExpensesMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, wages and related expenses [Member]", "label": "Salaries Wages And Related Expenses Member" } } }, "auth_ref": [] }, "ppbt_SalaryRelatedOtherPayablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SalaryRelatedOtherPayablesCurrent", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Salary related", "documentation": "The amount of current salary related payables.", "label": "Salary Related Other Payables Current" } } }, "auth_ref": [] }, "ppbt_SalesAgreementShares": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SalesAgreementShares", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales agreement", "documentation": "Sales agreement shares.", "label": "Sales Agreement Shares" } } }, "auth_ref": [] }, "ppbt_SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SalesGeneralandAdministrativeExpensesScheduleofSalesGeneralandAdministrativeExpensesDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "label": "Sales, General and Administrative Expenses - Schedule of Sales, General and Administrative Expenses (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfAssumptionsWereUsedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfAssumptionsWereUsedAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assumptions Were Used Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Carrying Amounts Of Right To Use Assets Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfCashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfCashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Cash And Cash Equivalents Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfCashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfCashAndCashEquivalentsLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Line Items]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Defined Contribution Plan in Respect of its Employees [Abstract]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfDetailsRegardingFairValueMeasurementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfDetailsRegardingFairValueMeasurementAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Details Regarding Fair Value Measurement Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfDetailsRegardingFairValueMeasurementTableTextBlock", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Details Regarding Fair Value Measurement", "documentation": "The entire disclosure for the fair value measurement.", "label": "Schedule Of Details Regarding Fair Value Measurement Table Text Block" } } }, "auth_ref": [] }, "ppbt_ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfExpensesRecognizedInTheConsolidatedFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Expenses Recognized In The Consolidated Financial Statements Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfFairValueMeasurementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfFairValueMeasurementAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Measurement Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfFinanceExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfFinanceExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Finance Expenses [Abstract]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfFinanceIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfFinanceIncomeAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Finance Income [Abstract]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Financial Instruments Measured At Fair Value Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Maturity Analysis Of The Companys Lease Liabilities Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfNumberOfRsusAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfNumberOfRsusAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Number of RSUs [Abstract]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfPostEmployeeBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfPostEmployeeBenefitsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Post-Employee Benefits [Abstract]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfRecordedExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfRecordedExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Recorded Expenses Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Research And Development Expenses Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfResearchAndDevelopmentExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfResearchAndDevelopmentExpensesLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Research and Development Expenses [Line Items]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Sales General And Administrative Expenses Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfSalesGeneralAndAdministrativeExpensesLineItems", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Sales, General and Administrative Expenses [Line Items]" } } }, "auth_ref": [] }, "ppbt_ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfSensitivityTestToPossibleChangesInExchangeRateAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Sensitivity Test To Possible Changes In Exchange Rate Abstract" } } }, "auth_ref": [] }, "ppbt_ScheduleOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ScheduleOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Share Capital Abstract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r253" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r257" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r256" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r262" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 }, "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable", "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Sales, General and Administrative Expenses total", "terseLabel": "General and administrative expenses", "label": "Selling, general and administrative expense" } } }, "auth_ref": [ "r408" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Sales, General and Administrative Expenses [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpenseMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable", "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense [member]", "label": "Selling, general and administrative expense [member]" } } }, "auth_ref": [ "r400", "r402" ] }, "ppbt_September2025OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "September2025OfferingMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofChangesinShareCapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "September 2025 Offering [Member]", "label": "September2025 Offering Member" } } }, "auth_ref": [] }, "ppbt_SeriesA1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SeriesA1WarrantsMember", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A-1 Warrants [Member]", "label": "Series A1 Warrants Member" } } }, "auth_ref": [] }, "ppbt_SeriesA2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SeriesA2WarrantsMember", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A-2 Warrants [Member]", "label": "Series A2 Warrants Member" } } }, "auth_ref": [] }, "ppbt_ServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ServiceProvidersMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Service providers [Member]", "label": "Service Providers Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "ppbt_ShareBasedPaymentArrangementsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShareBasedPaymentArrangementsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangements (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_ShareBasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShareBasedPaymentArrangementsMember", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Payment Arrangements [Member]", "label": "Share Based Payment Arrangements Member" } } }, "auth_ref": [] }, "ppbt_ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShareBasedPaymentArrangementsScheduleofAssumptionswereUsedDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangements - Schedule of Assumptions were Used (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShareBasedPaymentArrangementsScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofExpensesRecognizedintheConsolidatedFinancialStatementsTable" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangements - Schedule of Expenses Recognized in the Consolidated Financial Statements (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_ShareBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShareBasedPaymentsMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofResearchandDevelopmentExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments [Member]", "label": "Share Based Payments Member" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net of issuance expenses (in Dollars)", "label": "Share issue related cost" } } }, "auth_ref": [ "r401" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r245", "r249" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r184" ] }, "ppbt_ShortTermDepositsGuaranteedForHedgingTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShortTermDepositsGuaranteedForHedgingTransactions", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term deposits", "documentation": "Amount of short term deposits guaranteed for hedging transactions.", "label": "Short Term Deposits Guaranteed For Hedging Transactions" } } }, "auth_ref": [] }, "ppbt_ShortTermDepositsGuaranteedForLeasesAndCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "ShortTermDepositsGuaranteedForLeasesAndCredit", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term deposits guaranteed for leases and credit", "documentation": "Amount of short term deposits guaranteed for leases and credit.", "label": "Short Term Deposits Guaranteed For Leases And Credit" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term deposits", "label": "Short-term deposits, classified as cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r395" ] }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/ScheduleofPostEmployeeBenefitsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term benefits", "label": "Short-term employee benefits expense" } } }, "auth_ref": [ "r402" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r260" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total comprehensive loss attributable to:", "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "ppbt_StatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "StatementsTable", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statements Table" } } }, "auth_ref": [] }, "ppbt_StatutoryTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "StatutoryTaxRate", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory tax rate", "documentation": "Statutory tax rate.", "label": "Statutory Tax Rate" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r279", "r290", "r306", "r341" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "ppbt_StockholdersEquityReversesStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "StockholdersEquityReversesStockSplit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders equity reverse stock split", "documentation": "Stockholders equity reverse stock split.", "label": "Stockholders Equity Reverses Stock Split" } } }, "auth_ref": [] }, "ppbt_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_SubsequentEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "SubsequentEventsMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/GeneralDetails", "http://Purplebiotech.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Member]", "label": "Subsequent Events Member" } } }, "auth_ref": [] }, "ppbt_THMMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "THMMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "THM [Member]", "label": "THMMember" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit", "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense" } } }, "auth_ref": [ "r220", "r244" ] }, "ppbt_TaxesOnIncomeabstract": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TaxesOnIncomeabstract", "lang": { "en-us": { "role": { "label": "Taxes on Income [Abstract]" } } }, "auth_ref": [] }, "ppbt_TerminationExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TerminationExercisePrice", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination exercise price (in Dollars per share)", "documentation": "The exercise price of share options terminated.", "label": "Termination Exercise Price" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable", "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of Range [Member]", "verboseLabel": "Up 5% [Member]", "netLabel": "Top of range [member]", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r34", "r56", "r72", "r89", "r133", "r230", "r231", "r397" ] }, "ppbt_TotalAcquisitionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TotalAcquisitionAmount", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition amount", "documentation": "Amount of total acquisition .", "label": "Total Acquisition Amount" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r326" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r333" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Payables [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToRelatedParties", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable": { "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofOtherPayablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties - salary related", "label": "Current payables to related parties" } }, "en": { "role": { "documentation": "The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]" } } }, "auth_ref": [ "r406" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payable", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r248", "r406" ] }, "ifrs-full_TradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Other Payables [Abstract]" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r354" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r356" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ppbt_TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofRecordedExpensesDetailsTable", "presentation": [ "http://Purplebiotech.com/role/ScheduleofRecordedExpensesTable" ], "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties - Schedule of Recorded Expenses (Details) [Table]" } } }, "auth_ref": [] }, "ppbt_TransactionsandBalanceswithRelatedPartiesTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TransactionsandBalanceswithRelatedPartiesTablesLineItems", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Transactions and Balances with Related Parties [Abstract]", "label": "Transactionsand Balanceswith Related Parties Tables Line Items" } } }, "auth_ref": [] }, "ppbt_TransactionsandBalanceswithRelatedPartiesTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TransactionsandBalanceswithRelatedPartiesTablesTable", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" ], "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties (Tables) [Table]" } } }, "auth_ref": [] }, "ifrs-full_TravelExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TravelExpense", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Travel and car expenses", "label": "Travel expense, operating" } } }, "auth_ref": [ "r402" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r357" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r358" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r358" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r356" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r356" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r359" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r357" ] }, "ppbt_TryNovosTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "TryNovosTechnologiesMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TryNovo's Technologies [Member]", "label": "Try Novos Technologies Member" } } }, "auth_ref": [] }, "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsAxis", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r20" ] }, "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsDomain", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used." } } }, "auth_ref": [ "r20" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r9", "r73", "r74", "r75", "r77", "r95", "r97", "r98", "r141" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r9", "r73", "r74", "r75", "r77", "r95", "r97", "r98", "r141" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r90", "r161" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r90", "r161" ] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://Purplebiotech.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Balance in USD [Member]", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r353" ] }, "ppbt_UnrecognizedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "UnrecognizedResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized research and development expenses", "documentation": "The amount of unrecognized research and development expenses.", "label": "Unrecognized Research And Development Expenses" } } }, "auth_ref": [] }, "ppbt_UpRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "UpRangeOneMember", "presentation": [ "http://Purplebiotech.com/role/ScheduleofSensitivityTesttoPossibleChangesinExchangeRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Up 2% [Member]", "label": "Up Range One Member" } } }, "auth_ref": [] }, "ppbt_VestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "VestingPeriod", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "documentation": "It represents vesting period.", "label": "Vesting Period" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://Purplebiotech.com/role/ScheduleofSalesGeneralandAdministrativeExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, wages and related expenses", "label": "Wages and salaries, operating" } } }, "auth_ref": [ "r387" ] }, "ppbt_WarrantExercisableExpirePeriod": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantExercisableExpirePeriod", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercisable expire period", "documentation": "Warrant exercisable expire period.", "label": "Warrant Exercisable Expire Period" } } }, "auth_ref": [] }, "ppbt_WarrantExercisePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantExercisePricePerShare", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercise price per share (in Dollars per share)", "documentation": "Exercise price per share.", "label": "Warrant Exercise Price Per Share" } } }, "auth_ref": [] }, "ifrs-full_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantLiability", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability fair value (in Dollars)", "verboseLabel": "Warrants amount", "label": "Warrant liability" } }, "en": { "role": { "documentation": "The amount of warrant liabilities." } } }, "auth_ref": [ "r404" ] }, "ifrs-full_WarrantReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserve", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant inducement transaction gross (in Dollars)", "label": "Warrant reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } } }, "auth_ref": [ "r405" ] }, "ppbt_WarrantTermDescription": { "xbrltype": "stringItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantTermDescription", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant term, description", "documentation": "Description of warrant term.", "label": "Warrant Term Description" } } }, "auth_ref": [] }, "ppbt_WarrantsExercisableTerm": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantsExercisableTerm", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercisable term", "documentation": "Warrants exercisable term.", "label": "Warrants Exercisable Term" } } }, "auth_ref": [] }, "ppbt_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantsExercised", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised", "documentation": "Number of warrants exercised.", "label": "Warrants Exercised" } } }, "auth_ref": [] }, "ppbt_WarrantsIssuanceExpensesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantsIssuanceExpensesPaid", "crdr": "credit", "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants issuance expenses paid", "documentation": "The cash outflow for warrants issuance expenses paid, classified as financing activities.", "label": "Warrants Issuance Expenses Paid" } } }, "auth_ref": [] }, "ppbt_WarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantsIssued", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant purchased", "verboseLabel": "Warrants issued (in Shares)", "documentation": "Number of warrants issued.", "label": "Warrants Issued" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [member]", "verboseLabel": "Warrants [Member]", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r388" ] }, "ppbt_WarrantsTerm": { "xbrltype": "durationItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantsTerm", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants term", "documentation": "Period of time between issuance and maturity of warrants, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants Term" } } }, "auth_ref": [] }, "ppbt_WarrantsoneMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "WarrantsoneMember", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleofFairValueMeasurementTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "label": "Warrantsone Member" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Exercisable", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r86", "r159" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of option (in Dollars per share)", "label": "Weighted average exercise price of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r84", "r157" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Expired and forfeited during the year", "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r83", "r156" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Granted during the year", "label": "Weighted average exercise price of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r82", "r155" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://Purplebiotech.com/role/ScheduleofNumberandWeightedAverageExercisePricesofShareOptionsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, Outstanding beginning balance", "periodEndLabel": "Weighted average exercise price, Outstanding ending balance", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r81", "r85", "r154", "r158" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value options value (in Dollars)", "label": "Weighted average fair value at measurement date, share options granted" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r92" ] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://Purplebiotech.com/role/ShareBasedPaymentArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average contractual life", "label": "Weighted average remaining contractual life of outstanding share options" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price (in Dollars per share)", "label": "Weighted average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r88" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://Purplebiotech.com/role/ScheduleofAssumptionswereUsedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share Price - USD (in Dollars per share)", "label": "Weighted average share price, share options granted" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r91" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedStatementsofOperationsandOtherComprehensiveLossTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares used in calculation (in Shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r19" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r377" ] }, "ppbt_YissumsLicensedTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "YissumsLicensedTechnologyMember", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yissum\u2019s licensed technology [Member]", "verboseLabel": "Yissum\u2019s Licensed Technology [Member]", "label": "Yissums Licensed Technology Member" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r320" ] }, "ppbt_noncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "http://Purplebiotech.com/20251231", "localname": "noncontrollingInterests", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "documentation": "Non-controlling interests.", "label": "noncontrolling Interests" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "92", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_92&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_78_a&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "6.5.11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_6.5.11&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_g&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "121", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_121&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "203", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_203&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "250", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_c&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "da", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_da&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_b&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_f&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_f&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_d&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Section": "Example 11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&doctype=Implementation%20Guidance&dita_xref=IFRS05_ex11_TI", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_f&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r349": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r350": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r351": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r363": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r364": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r365": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r366": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r367": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r368": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r369": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r370": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r371": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r372": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r373": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r374": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r375": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r376": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r377": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r378": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r379": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r380": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r381": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r382": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r383": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r384": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r385": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }